Adynxx, Inc. (ADYX)

Market Cap	581.00
Revenue (ttm)	n/a
Net Income (ttm)	-10.57M
Shares Out	5.81M
EPS (ttm)	-1.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,300
Average Volume	820
Open	0.0002
Previous Close	0.0001
Day's Range	0.0001 - 0.0002
52-Week Range	n/a
Beta	-16.79
RSI	54.35
Earnings Date	n/a

About Adynxx

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: ADYX